We claim:

1. A compound according to the structure:

or



where R^1 is H, OH, F, Cl, Br, I, a C_1-C_6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group or a $\overset{O}{\overset{\|}{C}}$-$R_a$ group;

R_a is a H, OH, C_1-C_{10}, optionally substituted alkyl or alkenyl group, an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group;

R^2 is a $\overset{O}{\overset{\|}{C}}$-$R_b$ group;

R_b is a H, OH, C_1-C_{10}, optionally substituted alkyl or alkenyl group, an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group;

R^3 and R^6 are each independently selected from H, OH, F, Cl, Br, I, a C_1-C_6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane;

R^4 is a  group, wherein R_b is as described above; and

R^5 is a  group, wherein R_a is as described above,

with the proviso that at least one of R^1 and R^2 or R^4 and R^5 contains an R_a or R_b group which is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group;

or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.

2. The compound according to claim 2 wherein said chemical structure is



or



wherein R_a is OH or an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group; and Rb is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or an optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group.

3. The compound according to claim 2 having the chemical structure:



4. The compound according to claim 1 wherein R_a is an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group.

5. The compound according to claim 2 wherein R_a is an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group.

6. The compound according to claim 3 wherein R_a is an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group.

7. The compound according to claim 1 wherein R_b is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group.

8. The compound according to claim 3 wherein R_b is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group.

9. The compound according to claim 4 wherein R_b is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group.

10. The compound according to claim 1 wherein R_a is an optionally substituted O-(C_1-C_7 alkyl group) and R_b is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group.

11. The compound according to claim 1 wherein R_b is an amine group which is optionally substituted with a single cyclohexyl group, an optionally substituted phenyl group, or an optionally substituted benzyl group and R_a is a O-(C_1-C_3 alkyl) group or an O-phenyl group.

12. The compound according to claim 2 wherein R_b is an amine group which is optionally substituted with a single cyclohexyl group, an optionally substituted phenyl group, or an optionally substituted benzyl group and R_a is a O-(C_1-C_3 alkyl) group or an O-phenyl group.

13. The compound according to claim 3 wherein R_b is an amine group which is optionally substituted with a single cyclohexyl group, an optionally substituted phenyl group, or an optionally substituted benzyl group and R_a is a O-(C_1-C_3 alkyl) group or an O-phenyl group.

14. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier, additive or excipient.

15. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 in combination with a pharmaceutically acceptable carrier, additive or excipient.

16. A pharmaceutical composition comprising an effective amount of a compound according to claim 3 in combination with a pharmaceutically acceptable carrier, additive or excipient.

17. A pharmaceutical composition comprising an effective amount of a compound according to claim 4 in combination with a pharmaceutically acceptable carrier, additive or excipient.

18. A pharmaceutical composition comprising an effective amount of a compound according to claim 5 in combination with a pharmaceutically acceptable carrier, additive or excipient.

19. A pharmaceutical composition comprising an effective amount of a compound according to claim 6 in combination with a pharmaceutically acceptable carrier, additive or excipient.

20. A pharmaceutical composition comprising an effective amount of a compound according to claim 7 in combination with a pharmaceutically acceptable carrier, additive or excipient.

21. A pharmaceutical composition comprising an effective amount of a compound according to claim 8 in combination with a pharmaceutically acceptable carrier, additive or excipient.

22. A pharmaceutical composition comprising an effective amount of a compound according to claim 9 in combination with a pharmaceutically acceptable carrier, additive or excipient.

23. A pharmaceutical composition comprising an effective amount of a compound according to claim 10 in combination with a pharmaceutically acceptable carrier, additive or excipient.

24. A pharmaceutical composition comprising an effective amount of a compound according to claim 11 in combination with a pharmaceutically acceptable carrier, additive or excipient.

25. A pharmaceutical composition comprising an effective amount of a compound according to claim 12 in combination with a pharmaceutically acceptable carrier, additive or excipient.

26. A pharmaceutical composition comprising an effective amount of a compound according to claim 13 in combination with a pharmaceutically acceptable carrier, additive or excipient.

27. A method of treating a tumor or cancer in a patient in need of such treatment comprising administering to said patient an effective amount of a compound according to any of claims 1-13.

28. A method of treating a hyperproliferative disease in a patient in need thereof comprising administering to said patient an effective amount of a compound according to the chemical structure:



or



where R^1 is H, OH, F, Cl, Br, I, a C_1-C_6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group or a $\overset{O}{\overset{\|}{C}}$-$R_a$ group;

R_a is a H, OH, C_1-C_{10}, optionally substituted alkyl or alkenyl group, an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group, an amine group which is optionally

substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group;

R^2 is a $\overset{O}{\overset{\|}{C}}$-$R_b$ group;

R_b is a H, OH, C_1-C_{10}, optionally substituted alkyl or alkenyl group, an optionally substituted O-(C_1-C_7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group;

R^3 and R^6 are each independently selected from H, OH, F, Cl, Br, I, a C_1-C_6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane;

R^4 is a $\overset{O}{\overset{\|}{C}}$-$R_b$ group, wherein R_b is as described above; and

R^5 is a $\overset{O}{\overset{\|}{C}}$-$R_a$ group, wherein R_a is as described above,

with the proviso that at least one of R^1 and R^2 or R^4 and R^5 contains an R_a or R_b group which is an amine group which is optionally substituted with at least one C_1-C_{10} alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C_1-C_6) alkylenearyl group, (C_1-C_6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C_1-C_6) alkylene heteroaryl group or (C_1-C_6) alkylene heterocyclic group;

or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.

29. The method according to claim 28 wherein said hyperproliferative disease is psoriasis, genital warts, hyperkeratosis, ichthyosis, keratoderma or lichen planus.

30. A method of inhibiting a cellular kinase in cells of a patient comprising exposing said cells to an effective amount of a compound according to claim 1.